SNDX Q1 2023 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$46M

Net Income

-$41M

EPS (Diluted)

$-0.59

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$39M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$460M

Total Liabilities

$24M

Stockholders' Equity

$436M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$46M	-$37M	-24.8%
Net Income	-$41M	-$37M	-10.6%